Drug Trial Radar · NCT06106074
Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Aug 10, 2020
Primary completion
May 23, 2022
Study completion May 23, 2022
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, four-part, Phase I, first in human (FIH) study to assess the tolerability and pharmacokinetics (PK) of ascending single and 14-day repeated oral doses of SAR442168 with a food effect investigation in healthy adult participants. * In Part 1a: The tolerability and safety of SAR442168 and the pharmacokinetic parameters of SAR442168 and metabolite(s)after ascending single oral doses in fasted and fed conditions * In Part 1b: The relationship of PK of SAR442168 and metabolite(s) in cerebrospinal fluid (CSF) to that in plasma after single oral doses given in fed conditions (moderate-fat meal) * In Part 1c: The effect of a high-fat meal on the pharmacokinetics of SAR442168 and metabolite(s) (high-fat) * In Part 1d: The effect of a high-fat meal on the pharmacokinetics of SAR442168 and metabolite(s) (standardized high-fat meal) * In Part 2: The tolerability and safety of SAR442168 and the pharmacokinetic parameters of SAR442168 and metabolite(s) after 14-day ascending repeated oral doses of SAR442168 given in fed conditions (moderate-fat meal).
Conditions
- Multiple Sclerosis
Interventions
TolebrutinibDrug
Tablet, oral
PlaceboDrug
Tablet, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1a and Part 2: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs)Time frame: Part 1a: Day 1 to approximately Day 14 Part 2: Day 1 to approximately Day 21
- Part 1b: Total (free and bound) SAR442168 concentrations in CSFTime frame: From Day 1 to Day 3
- Part 1b: Total (free and bound) SAR442168 metabolite(s) concentrations in CSFTime frame: From Day 1 to Day 3
- Part 1c and Part 1d: Maximum plasma concentration observed (Cmax) ratio fed/fast of SAR442168Time frame: From Day 1 to Day approximately 14
- Part 1c and Part1d: Cmax ratio fed/fasted of SAR442168 metabolite(s)Time frame: From Day 1 to Day approximately 14
- Part 1c and Part 1d: Area under the plasma concentration versus time curve (AUC) ratio fed/fast of SAR442168Time frame: From Day 1 to Day approximately 14
- Part 1c and Part1d: AUC ratio fed/fast of SAR442168 metabolite(s)Time frame: From Day 1 to Day approximately 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Orleans Clinical Research Site Number : 8400001
Knoxville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.